APR 29, 2021 12:25 PM PDT

Current and upcoming pharma collaboration and IVD strategy

Speaker
  • President, Clinical Next Generation Sequencing, Thermo Fisher Scientific
    Biography

      Garret Hampton, PhD., is currently President, Clinical Sequencing and Oncology at ThermoFisher Scientific, responsible for leading the company’s clinical next generation sequencing strategy. Prior to joining Thermo Fisher Scientific, Garret was Senior Vice President, Clinical Genomics, at Illumina, responsible for the development of sequencing-based solutions in oncology, reproductive health and whole genome sequencing for the diagnosis of rare disease. Before joining Illumina, Garret held a variety of leadership positions at Genentech / Roche, Celgene, and The Genomics Institute of the Novartis Research Foundation, focused on drug target discovery, drug development and precision medicine. Prior to moving into industry, Garret was Assistant Professor of Medicine at UCSD, San Diego after a 2-year postdoctoral fellowship at the Salk Institute for Biological Studies. He received his PhD from the Imperial Cancer Research Fund (now Cancer Research UK) under Sir Walter Bodmer. He has authored over 150 peer reviewed articles and reviews, with 10,000 lifetime citations.


    Abstract

    Thermo Fisher Scientific have spearheaded the development and democratization of next-generation sequencing, a technology that has fueled research in precision oncology and will play a key part in its broad implementation for patients. Dr. Garret Hampton, president of the Clinical Sequencing Division will talk current and future Oncomine IVD and companion diagnostics (CDx) solutions and namely about plans for IVD submissions of future Oncomine Dx Express Test on Genexus System.


    Show Resources
    You May Also Like
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JAN 21, 2021 8:00 AM PST
    JAN 21, 2021 8:00 AM PST
    Date: January 21, 2021 Time: 8:00am (PST), 11:00am (EST) Today, critical reagent characterization is a key component in the overall workflow to establish robust ligand binding assays (e.g.,...
    NOV 19, 2020 8:00 AM GMT
    C.E. CREDITS
    NOV 19, 2020 8:00 AM GMT
    Date: November 19, 2020 Time: 12:00am (PDT), 9:00am (CET), 4:00pm (SGT) We present split-FISH, a multiplexed fluorescence in situ hybridization method that leverages a split-probe design to...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    MAR 30, 2021 8:00 AM PDT
    MAR 30, 2021 8:00 AM PDT
    DATE: March 30, 2021 TIME: 08:00am PST In this talk, we will discuss the value of moving towards modular and automated, closed-system technologies designed to enable scalable and cost-effect...
    Loading Comments...
    Show Resources